Machine signal
Active cluster sell — 5 distinct insiders, $12.5M, window ends Oct 1, 2026.
Figures computed from official regulatory filings — .
Analysttarget 73.92 USD (+79%) · consensus 4.79/5 · 14 buy · 0 hold · 0 sell
Ownershipinsiders 6.22% · institutions 115.48% · short 20.4% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Enliven Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
43 buys364 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BALL KRISTINE M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Garland J. Scott | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Garland J. Scott | Sell | $606.7K | SEC |
| Garland J. Scott | Exercise | $201.1K | SEC |
| Hohl Benjamin | Sell | $111.3K | SEC |
| Hohl Benjamin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hohl Benjamin | Sell | $14.9K | SEC |
| Collins Helen Louise | Sell | $145.9K | SEC |
| Collins Helen Louise | Exercise | $12.4K | SEC |
| Hohl Benjamin | Sell | $176.9K | SEC |
| Hohl Benjamin | Exercise | $59.1K | Unusual size | SEC |
| Collins Helen Louise | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Collins Helen Louise | Sell | $93.5K | SEC |
| Collins Helen Louise | Sell | $12.4K | SEC |
| Hohl Benjamin | Sell | $82.4K | SEC |
| Collins Helen Louise | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hohl Benjamin | Sell | $270.2K | Unusual size | SEC |
| Collins Helen Louise | Sell | $65.3K | SEC |
| Collins Helen Louise | Sell | $227.6K | SEC |
| Collins Helen Louise | Exercise | $12.4K | SEC |
| Derynck Mika K | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Derynck Mika K | Exercise | $460.4K | SEC |
| Derynck Mika K | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Derynck Mika K | Exercise | $216.7K | SEC |
| Derynck Mika K | Exercise | $696.9K | SEC |